

ATZUMI - (EQ 5.2MG BASE ; Powder)

Generic Name	DIHYDROERGOTAMINE MESYLATE	Innovator	SATSUMA PHARMS
Dosage	EQ 5.2MG BASE ; Powder	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.